On September 29, 2014, Eli Lilly filed its memorial in its NAFTA challenge against Canada, asserting that the Canadian judiciary’s application of the promise doctrine to Eli Lilly patents covering the drugs STRATTERA® (atomoxetine) and ZYPREXA® (olanzapine) contravenes Canada’s obligations under the North American Free Trade Agreement (NAFTA) and the Patent Cooperation Treaty (PCT). Eli Lilly is seeking an amount in damages of not less than CAD 500 million.
For prior E-TIPS® coverage on the progress of Eli Lilly’s NAFTA challenge, click here.
Summary by: Junyi Chen
E-TIPS® ISSUE
14 11 05
Disclaimer: This Newsletter is intended to provide readers with general information on legal developments in the areas of e-commerce, information technology and intellectual property. It is not intended to be a complete statement of the law, nor is it intended to provide legal advice. No person should act or rely upon the information contained in this newsletter without seeking legal advice.
E-TIPS is a registered trade-mark of Deeth Williams Wall LLP.
